



ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

AMGEN IN HONG KONG

Amgen Hong Kong was established in 2016 to make our innovative medicines available to patients in Hong Kong and Macau suffering from serious illnesses. Amgen's entry into this market enhances the exchange of scientific ideas, fosters more research collaborations and brings innovative therapies to help patients with serious illnesses.

MILESTONES: TRANSFORMING HEALTHCARE IN HONG KONG

Our achievements in Hong Kong reinforce Amgen's commitment to delivering innovative and high-quality treatments and biosimilar medicines to patients with chronic diseases and critical illnesses.

2014–2017: Acquiring Rights and Approvals to Innovative, Lifesaving Medicines

Between 2014 and 2016, Amgen re-acquired the marketing authorization of five innovative medicines in Hong Kong/Macau, and is now the marketing authorization holder for Neupogen® (filgrastim), Neulastim® (pegfilgrastim), Prolia® (denosumab), Vectibix® (panitumumab) and Xgeva® (denosumab). Additionally, Repatha® (evolocumab) was granted marketing approval by the Hong Kong Department of Health (May 2016) and import permit by the Macau Health Bureau (November 2017). Kyprolis® (carfilzomib) was granted marketing approval by the Hong Kong Department of Health (December 2016) and import permit by the Macau Health Bureau (February 2017).

2016–2019: Growing Commercial Capabilities to Serve Patients in Hong Kong

Amgen began establishing its commercial presence in Hong Kong in May 2016. Established initially with only three full-time staff, we were in full operation under Amgen Asia Holdings Limited by October 2016, with an expanded team of 10 Sales and Marketing staff. By investing in people and maximizing potential of talents, we expanded rapidly and Amgen Hong Kong Affiliate was officially established as a legal entity in 2018. Currently, with almost 50 full-time staff, Amgen Hong Kong offers full commercial capability, covering treatments for six therapeutic areas: bone health, cardiology, oncology, rheumatology, inflammatory and hematology. We served approximately 30,000 patients in Hong Kong and Macau in 2019.

STRENGTHENING HEALTHCARE SYSTEMS

Amgen Hong Kong is dedicated to taking an innovative, responsible and sustainable approach to build healthcare capabilities and improve the care of patients in the market. To this end, we work with regional and local stakeholders to promote healthcare systems that work and save costs. We also partner with non-governmental organizations in Hong Kong to run patient assistance programs, allowing patients to access appropriate treatment and timely care throughout their treatment journey. As part of Amgen's mission to further the advancement of healthcare and health literacy, we have invested over HK\$100 million in medical education, policy development and commercialization in the local healthcare sector since 2016. We also partner with patient groups to deliver disease education programs to the general public, with the aim of sharing and imparting pertinent scientific knowledge to the community.

PUTTING PEOPLE FIRST

In addition to caring for patients and their families, Amgen also takes care of its people contributing to these advances. We recognize that our staff is our best asset and aim to secure their overall wellbeing and those whose lives they touch every day. A number of family-friendly initiatives are available to our staff, including flexible working arrangements and work-from-home policies. Amgen Hong Kong earned

AMGEN MISSION

To serve patients

AMGEN QUICK FACTS

Global Headquarters

Thousand Oaks, California

JAPAC Headquarters

Hong Kong

Staff

Approximately 20,000 worldwide

50 staff in Amgen Hong Kong

Stock Listing

NASDAQ: AMGN

Amgen Hong Kong

Leadership

Kara Cheung, General Manager,
Hong Kong & Macau

Amgen Hong Kong

Contact Details

Suite 405-12, 4/F,
One Island East,
18 Westlands Road,
One Island East,
Hong Kong
Tel: +852 2808 3988

Products in Hong Kong

- AMGEVITA™ (biosimilar adalimumab)
- BLINCYTO® (blinatumomab)
- EVENITY® (romosozumab)
- KANJINTI® (biosimilar trastuzumab)
- KYPROLIS® (carfilzomib)
- MVASI™ (biosimilar bevacizumab)
- NEULASTIM® (pegfilgrastim)
- NEUPOGEN® (filgrastim)
- PARSABIV® (etelcalcetide)
- PROLIA® (denosumab)
- REPATHA® (evolocumab)
- VECTIBIX® (panitumumab)
- XGEVA® (denosumab)

the Caring Company recognition in 2019-2021 and HR Asia's 'Best Company for Work in Asia' award in 2020, which commend business organizations in Hong Kong that demonstrate good corporate citizenship.

Amgen encourages its staff to have fulfilling and meaningful careers through challenging assignments, active career development and coaching, and individual rewards. Our leaders review, retain and develop diverse team members, set challenging performance expectations and provide timely feedback, ultimately building empowered teams that put patients first.

ENVIRONMENTAL RESPONSIBILITY AND SUSTAINABILITY

Sustainable operations can reduce environmental impact, improve efficiency and create value. Under the local AMGreen initiative, we have been strategic in our approaches to reduce waste, recycle and conserve energy. Besides quarterly lunch-and-learn sessions with sustainability organizations, we also successfully organized our first beach cleanup in September 2019, where almost 80 kg of waste was collected. For more details on Amgen environmental initiatives, please visit [Amgen Global Website](#).

SUPPORTING THE NEXT GENERATION OF RESEARCH EXPERTISE

The Amgen Foundation, established in 1991, seeks to advance excellence in science education to inspire the next generation of innovators and strengthen communities where Amgen staff live and work. The Foundation is the principal channel for Amgen's corporate philanthropy and since 2014, it has contributed nearly US\$4 million to programs in the Japan, Australia and Asia Pacific (JAPAC) region, including **Amgen Biotech Experience (ABE)** and **Amgen Scholars**.

Amgen Biotech Experience (ABE)

Partnering with the Chinese University of Hong Kong, ABE Hong Kong is tailored to enrich the Diploma of Secondary Education biology curriculum. It fills the gap between theory learning and practical work, as well as constituting an important part of science, technology, engineering and mathematics (STEM) education. Since 2016, the program has reached 43 schools, 85 teachers, 73 school lab technicians and over 2,900 students.

Through ABE Hong Kong, Amgen nurtures a community of science teachers with pedagogical, curricular and technical competencies in biotechnology education, and ultimately promote biotechnology as a key element of science learning in Hong Kong.

Amgen Scholars

Launched in 2006, Amgen Scholars opens the opportunity for undergraduate students to apply for a summer science learning experience. Students engage in cutting-edge research experiences and learn more about biotechnology and drug discovery. In JAPAC, four renowned universities have hosted this Program: Kyoto University and The University of Tokyo in Japan, National University of Singapore in Singapore, and Tsinghua University in China.

A LEADING BIOTECHNOLOGY COMPANY IN JAPAC

Hong Kong has been a key clinical development hub for Amgen in JAPAC since 2007, facilitating collaboration between Amgen and local researchers, and leveraging their expertise to advance Amgen's clinical pipeline. Building on this legacy, the Amgen JAPAC regional network is headquartered in Hong Kong to oversee operations across the region. Amgen JAPAC serves over 1 million patients and is committed to serving Asian communities by building on its track record as a trusted provider of medicine and using science and biotechnology to improve health for patients and societies.

Pioneering Excellence in Biomanufacturing

As a global leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering innovative and high-quality medicines to Asian patients. This record of success is supported by state-of-the-art facilities and global manufacturing network, as well as regional capabilities to ensure quality and supply. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation. Furthermore, our leadership as a biosimilar producer continues to provide more options to the patients, helping to make the healthcare system more sustainable.

Public Information

HK-06059-AMGEN-2021-Apr| Date approved: Apr 2021

For more information on Amgen Hong Kong, visit www.amgen.com.hk

Click on the links below to learn more:

[Amgen Foundation](#)

[Amgen Biotech Experience](#)

[Amgen Scholars](#)

[Amgen Biosimilars](#)